Unity Biotechnology (STU:9U90) 6-Month Share Buyback Ratio : -0.10% (As of Dec. 2024 )

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Unity Biotechnology's current 6-Month Share Buyback Ratio was -0.10%.

Competitive Comparison of Unity Biotechnology's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, Unity Biotechnology's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unity Biotechnology's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Unity Biotechnology 6-Month Share Buyback Ratio Calculation

Unity Biotechnology's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(16.848	-	16.865)	/	16.848
	=	-0.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology (STU:9U90) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Unity Biotechnology 6-Month Share Buyback Ratio Related Terms

Unity Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (STU:9U90) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

UBX:USA 0YC0:UK 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Unity Biotechnology Headlines

No Headlines